News

Inaphaea is pleased to announce the execution of an exclusive licence agreement with UK-based Dominion Biotech Ltd for Inaphaea’s PredictRx® platform. PredictRx is a personalised cancer screening service whereby a patient’s tumour sample is processed into Patient Derived Cells (PDCs) and subjected to a comprehensive drug combination screening panel to determine optimal chemotherapy treatment protocols.…

Life science innovation company ValiRx has announced the appointment of a Director of Research and expanded the lab team of its research subsidiary, Inaphaea BioLabs. Michelle Barnard joins ValiRx to head up the company’s scientific programmes and coordinate client projects with Inaphaea BioLabs, providing technical and commercial expertise and oversight.  Inaphaea BioLabs, based at MediCity…

In December, Roy took part in a two-week internship where he was able to gain valuable experience in the Inaphaea labs.  During his internship Roy was able to draw on the skills he had acquired during his MSc in Molecular Cell Biology at Nottingham Trent University as he received a hands-on introduction to cancer research…

Inaphaea BioLabs has grown significantly since it was established in 2023. We have made great strides in commercialising our patient derived cell (PDC) bank and now offer cells for purchase and testing services from our collection of over 470 PDCs, representing 66 types of cancer. 2024 has seen Inaphaea forge several new partnerships and collaborations,…

Inaphaea is pleased to confirm it is collaborating on a project using funds from The Open University’s Higher Education Innovation Fund (HEIF) to characterise the subtype and drug sensitivity of up to 12 prostate cancer lines from Inaphaea’s Patient Derived Cell (“PDC”) bank. The project will utilise The Open University’s expertise in characterisation of Neuroendocrine Prostate…

This news round-up covers our latest news and updates from September and October. It has been a busy month for Inaphaea, with our parent company ValiRx signing several agreements with CROs and biotechs around the world as we move forward with our growth plans. News round-up: Autumn 2024 Evaluation and commercial use agreement with BioReperia…

Inaphaea BioLabs’ collaboration partner Inspiralis is a leading biotech specialising in DNA modifying enzymes and their substrates. The company supports preclinical development of anti-infective and anti-cancer compounds, either through the supply of its high-quality products or through provision of contract research services in the form of drug screening and mode of action studies. To find…

Inaphaea BioLabs’ collaboration partner DefiniGEN provides technology to revolutionise liver models for drug efficacy and toxicology screening, utilising a platform that enables the large-scale generation of hepatocyte-like cells (Opti-HEP) with comparable functionality to primary human hepatocytes. To find out more, we sat down with Heidi Kingdon Jones, Chief Business Officer at DefiniGEN to discuss the company’s…